The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Global Lentivirus Particle market is projected to reach US$ 373.3 million in 2029, increasing from US$ 279 million in 2022, with the CAGR of 4.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Lentivirus Particle market research.
Lentivirus particles have been widely used in biomedical research, particularly in the field of gene therapy and gene delivery. Lentiviruses, such as the human immunodeficiency virus (HIV), have been modified to be non-replicative and used as vectors to deliver genetic material into target cells. This delivery system enables the introduction of specific genes or genetic modifications into cells for various applications, including research, drug development, and potential therapeutic interventions.
The lentivirus particle market has seen significant growth due to the expanding interest in gene therapy, gene editing, and other genetic research applications. Lentiviral vectors offer several advantages, including their ability to infect both dividing and non-dividing cells, stable gene expression over extended periods, and a broad range of target cell compatibility.
Future development trends in the lentivirus particle market include:
Enhanced Safety and Efficiency: Ongoing research aims to improve the safety and efficiency of lentivirus-based gene delivery systems. This includes developing new vector designs, modifying viral components, and optimizing transduction protocols.
Targeted Delivery: Efforts are being made to enhance the specificity of lentiviral vectors by incorporating targeting ligands or using tissue-specific promoters. This enables more precise delivery of therapeutic genes to specific cell types or tissues.
Large-Scale Production: As demand for lentivirus particles increases, there is a need for scalable and cost-effective production methods. Advances in large-scale manufacturing techniques and purification processes are anticipated to support the growth of the market.
Regulatory Considerations: The lentivirus particle market is subject to regulatory oversight due to safety concerns associated with the use of viral vectors. Future developments may involve addressing regulatory requirements and guidelines to ensure safe and effective use of lentiviral-based therapies.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Lentivirus Particle market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
- AMSBIO
- Creative Biogene
- Cellomics Technology
- GenTarget
- Takara Bio
- GeneCopoeia
- OriGene
- GenScript
- Addgene
- System Biosciences
- BPS Bioscience
- Charles River
- Santa Cruz Biotechnology
- Sigma-Aldrich
Segment by Type
- Custom-made
- Pre-made
Segment by Application
- Gene Expression
- Gene Editing
- Cell Line Development
- Gene Therapy
- Others
By Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Russia, Nordic Countries, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea,Southeast Asia, India, Australia, Rest of Asia)
- Latin America (Mexico, Brazil, Rest of Latin America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
The Lentivirus Particle report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Lentivirus Particle Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Custom-made
1.2.3 Pre-made
1.3 Market by Application
1.3.1 Global Lentivirus Particle Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Gene Expression
1.3.3 Gene Editing
1.3.4 Cell Line Development
1.3.5 Gene Therapy
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Lentivirus Particle Market Perspective (2018-2029)
2.2 Lentivirus Particle Growth Trends by Region
2.2.1 Global Lentivirus Particle Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Lentivirus Particle Historic Market Size by Region (2018-2023)
2.2.3 Lentivirus Particle Forecasted Market Size by Region (2024-2029)
2.3 Lentivirus Particle Market Dynamics
2.3.1 Lentivirus Particle Industry Trends
2.3.2 Lentivirus Particle Market Drivers
2.3.3 Lentivirus Particle Market Challenges
2.3.4 Lentivirus Particle Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Lentivirus Particle Players by Revenue
3.1.1 Global Top Lentivirus Particle Players by Revenue (2018-2023)
3.1.2 Global Lentivirus Particle Revenue Market Share by Players (2018-2023)
3.2 Global Lentivirus Particle Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Lentivirus Particle Revenue
3.4 Global Lentivirus Particle Market Concentration Ratio
3.4.1 Global Lentivirus Particle Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Lentivirus Particle Revenue in 2022
3.5 Lentivirus Particle Key Players Head office and Area Served
3.6 Key Players Lentivirus Particle Product Solution and Service
3.7 Date of Enter into Lentivirus Particle Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Lentivirus Particle Breakdown Data by Type
4.1 Global Lentivirus Particle Historic Market Size by Type (2018-2023)
4.2 Global Lentivirus Particle Forecasted Market Size by Type (2024-2029)
5 Lentivirus Particle Breakdown Data by Application
5.1 Global Lentivirus Particle Historic Market Size by Application (2018-2023)
5.2 Global Lentivirus Particle Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Lentivirus Particle Market Size (2018-2029)
6.2 North America Lentivirus Particle Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Lentivirus Particle Market Size by Country (2018-2023)
6.4 North America Lentivirus Particle Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Lentivirus Particle Market Size (2018-2029)
7.2 Europe Lentivirus Particle Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Lentivirus Particle Market Size by Country (2018-2023)
7.4 Europe Lentivirus Particle Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Lentivirus Particle Market Size (2018-2029)
8.2 Asia-Pacific Lentivirus Particle Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Lentivirus Particle Market Size by Region (2018-2023)
8.4 Asia-Pacific Lentivirus Particle Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Lentivirus Particle Market Size (2018-2029)
9.2 Latin America Lentivirus Particle Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Lentivirus Particle Market Size by Country (2018-2023)
9.4 Latin America Lentivirus Particle Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Lentivirus Particle Market Size (2018-2029)
10.2 Middle East & Africa Lentivirus Particle Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Lentivirus Particle Market Size by Country (2018-2023)
10.4 Middle East & Africa Lentivirus Particle Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AMSBIO
11.1.1 AMSBIO Company Detail
11.1.2 AMSBIO Business Overview
11.1.3 AMSBIO Lentivirus Particle Introduction
11.1.4 AMSBIO Revenue in Lentivirus Particle Business (2018-2023)
11.1.5 AMSBIO Recent Development
11.2 Creative Biogene
11.2.1 Creative Biogene Company Detail
11.2.2 Creative Biogene Business Overview
11.2.3 Creative Biogene Lentivirus Particle Introduction
11.2.4 Creative Biogene Revenue in Lentivirus Particle Business (2018-2023)
11.2.5 Creative Biogene Recent Development
11.3 Cellomics Technology
11.3.1 Cellomics Technology Company Detail
11.3.2 Cellomics Technology Business Overview
11.3.3 Cellomics Technology Lentivirus Particle Introduction
11.3.4 Cellomics Technology Revenue in Lentivirus Particle Business (2018-2023)
11.3.5 Cellomics Technology Recent Development
11.4 GenTarget
11.4.1 GenTarget Company Detail
11.4.2 GenTarget Business Overview
11.4.3 GenTarget Lentivirus Particle Introduction
11.4.4 GenTarget Revenue in Lentivirus Particle Business (2018-2023)
11.4.5 GenTarget Recent Development
11.5 Takara Bio
11.5.1 Takara Bio Company Detail
11.5.2 Takara Bio Business Overview
11.5.3 Takara Bio Lentivirus Particle Introduction
11.5.4 Takara Bio Revenue in Lentivirus Particle Business (2018-2023)
11.5.5 Takara Bio Recent Development
11.6 GeneCopoeia
11.6.1 GeneCopoeia Company Detail
11.6.2 GeneCopoeia Business Overview
11.6.3 GeneCopoeia Lentivirus Particle Introduction
11.6.4 GeneCopoeia Revenue in Lentivirus Particle Business (2018-2023)
11.6.5 GeneCopoeia Recent Development
11.7 OriGene
11.7.1 OriGene Company Detail
11.7.2 OriGene Business Overview
11.7.3 OriGene Lentivirus Particle Introduction
11.7.4 OriGene Revenue in Lentivirus Particle Business (2018-2023)
11.7.5 OriGene Recent Development
11.8 GenScript
11.8.1 GenScript Company Detail
11.8.2 GenScript Business Overview
11.8.3 GenScript Lentivirus Particle Introduction
11.8.4 GenScript Revenue in Lentivirus Particle Business (2018-2023)
11.8.5 GenScript Recent Development
11.9 Addgene
11.9.1 Addgene Company Detail
11.9.2 Addgene Business Overview
11.9.3 Addgene Lentivirus Particle Introduction
11.9.4 Addgene Revenue in Lentivirus Particle Business (2018-2023)
11.9.5 Addgene Recent Development
11.10 System Biosciences
11.10.1 System Biosciences Company Detail
11.10.2 System Biosciences Business Overview
11.10.3 System Biosciences Lentivirus Particle Introduction
11.10.4 System Biosciences Revenue in Lentivirus Particle Business (2018-2023)
11.10.5 System Biosciences Recent Development
11.11 BPS Bioscience
11.11.1 BPS Bioscience Company Detail
11.11.2 BPS Bioscience Business Overview
11.11.3 BPS Bioscience Lentivirus Particle Introduction
11.11.4 BPS Bioscience Revenue in Lentivirus Particle Business (2018-2023)
11.11.5 BPS Bioscience Recent Development
11.12 Charles River
11.12.1 Charles River Company Detail
11.12.2 Charles River Business Overview
11.12.3 Charles River Lentivirus Particle Introduction
11.12.4 Charles River Revenue in Lentivirus Particle Business (2018-2023)
11.12.5 Charles River Recent Development
11.13 Santa Cruz Biotechnology
11.13.1 Santa Cruz Biotechnology Company Detail
11.13.2 Santa Cruz Biotechnology Business Overview
11.13.3 Santa Cruz Biotechnology Lentivirus Particle Introduction
11.13.4 Santa Cruz Biotechnology Revenue in Lentivirus Particle Business (2018-2023)
11.13.5 Santa Cruz Biotechnology Recent Development
11.14 Sigma-Aldrich
11.14.1 Sigma-Aldrich Company Detail
11.14.2 Sigma-Aldrich Business Overview
11.14.3 Sigma-Aldrich Lentivirus Particle Introduction
11.14.4 Sigma-Aldrich Revenue in Lentivirus Particle Business (2018-2023)
11.14.5 Sigma-Aldrich Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
